Showing results (2181-2190 of 2,272) with videos related to

Sort By:
Pageof 228
Nature Communications|January 23, 2021
SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaquesYashavanth Shaan Lakshmanappa, Sonny R Elizaldi, Jamin W Roh, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Prior vaccination enhances immune responses during SARS-CoV-2 breakthrough infection with early activation of memory T cells followed by production of potent neutralizing antibodiesMark M Painter, Timothy S Johnston, Kendall A Lundgreen, et al.
Iscience|August 18, 2025
Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccineYohana Martínez-Balboa, Linmar Rodríguez-Guilarte, Constanza Méndez, et al.
European Stroke Journal|April 17, 2024
Early seizures and risk of epilepsy and death after intracerebral haemorrhage: The MUCH ItalyAlessandro Pezzini, Barbara Tarantino, Marialuisa Zedde, et al.
Immunity|August 12, 2022
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccinationYu Gao, Curtis Cai, David Wullimann, et al.
Nature Immunology|September 22, 2023
Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infectionMark M Painter, Timothy S Johnston, Kendall A Lundgreen, et al.
Annals of Neurology|June 5, 2023
Risk Profile of Patients with Spontaneous Cervical Artery DissectionElisabetta Del Zotto, Mario Grassi, Marialuisa Zedde, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 14, 2020
Long-term outcome of cervical artery dissection : IPSYS CeAD: study protocol, rationale, and baseline data of an Italian multicenter research collaborationSonia Bonacina, Mario Grassi, Marialuisa Zedde, et al.
Elife|October 13, 2022
Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trialNicolás M S Gálvez, Gaspar A Pacheco, Bárbara M Schultz, et al.
BMC Medicine|December 15, 2025
A booster dose of an inactivated SARS-CoV-2 vaccine targeting virus variants sustains protective humoral and cellular immunityConstanza Méndez, Linmar Rodríguez-Guilarte, Pablo A Palacios, et al.
Pageof 228